Form 4: Milestone Pharmaceuticals Director Stuart Duty Granted 40,000 Stock Options

Milestone Pharmaceuticals Inc. Director Stuart Duty has been granted 40,000 stock options with an exercise price of $1.75, vesting over 12 months.

Summary

• Stuart Duty, a Director of Milestone Pharmaceuticals Inc. (MIST), was granted 40,000 stock options.
• The options have an exercise price of $1.75 per share.
• The transaction date for this grant was June 10, 2025.
• The options will vest in twelve equal monthly installments, commencing on July 10, 2025.
• Full vesting will occur by the date of the next annual meeting of stockholders, contingent on Mr. Duty's continued service.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Stuart Duty beneficially owns 40,000 derivative securities directly.

Sentiment

Score: 6

Explanation: Slightly positive, as it represents a standard compensation practice that aligns director interests with shareholder value, without indicating any negative operational or financial news.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.

Future Outlook

The stock options granted to Director Stuart Duty are subject to a vesting schedule, with installments beginning on July 10, 2025, and full vesting by the next annual meeting, contingent on continued service. This indicates a future commitment and incentive structure for the director.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, serving as a key component of executive and director compensation packages. It aims to align the interests of leadership with long-term shareholder value, particularly in a sector where long development cycles and regulatory milestones are prevalent.

Related Party Transactions

• The grant of 40,000 stock options to Stuart Duty, a Director of Milestone Pharmaceuticals Inc., constitutes a transaction with a related party.

Stakeholder Impact

• Shareholders: The grant of options to a director can align their interests with shareholders, potentially leading to decisions that enhance long-term stock value.
• Employees: While not directly impacting general employees, such grants are part of a broader compensation philosophy that can influence overall company culture and retention strategies for key personnel.

Next Steps

• The stock options will begin vesting in twelve equal monthly installments starting July 10, 2025.
• The options will be fully vested by the date of the next annual meeting of stockholders, provided Stuart Duty continues to provide service.

Key Dates

Keywords

Milestone Pharmaceuticals, MIST, Stock Option, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Vesting Schedule